Evidence-based guidelines for the use of biochemical markers of bone turnover in the selection and monitoring of bisphosphonate treatment in osteoporosis: a consensus document of the Belgian Bone Club

Objectives:  To review the clinical value of bone turnover markers (BTM), to initiate and/or monitor anti‐resorptive treatment for osteoporosis compared with bone mineral density (BMD) and to evaluate suitable BTM and changes in BTM levels for significance of treatment efficiency.

[1]  P. Gerdhem,et al.  Prediction of bone loss using biochemical markers of bone turnover , 2007, Osteoporosis International.

[2]  Richard Eastell,et al.  Effect of monitoring bone turnover markers on persistence with risedronate treatment of postmenopausal osteoporosis. , 2007, The Journal of clinical endocrinology and metabolism.

[3]  S. Papapoulos,et al.  Changes in bone remodelling and antifracture efficacy of intermittent bisphosphonate therapy: implications from clinical studies with ibandronate , 2007, Postgraduate Medical Journal.

[4]  B. Clarke,et al.  Efficacy and tolerability of once-monthly oral ibandronate in postmenopausal osteoporosis: 2 year results from the MOBILE study , 2007 .

[5]  D. Bauer,et al.  Potential for bone turnover markers to cost-effectively identify and select post-menopausal osteopenic women at high risk of fracture for bisphosphonate therapy , 2007, Osteoporosis International.

[6]  J. Reginster,et al.  Clinical utility of a pharmacostatistical model for ibandronate in postmenopausal osteoporosis. , 2006, Current drug metabolism.

[7]  M. Seibel.  Biochemical markers of bone turnover part II: clinical applications in the management of osteoporosis. , 2006, The Clinical biochemist. Reviews.

[8]  M. Drezner,et al.  Efficacy and tolerability of once-monthly oral ibandronate in postmenopausal osteoporosis: 2 year results from the MOBILE study , 2005, Annals of the rheumatic diseases.

[9]  D. Bauer,et al.  Pretreatment Levels of Bone Turnover and the Antifracture Efficacy of Alendronate: The Fracture Intervention Trial , 2005, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[10]  C. Cooper,et al.  A new concept for bisphosphonate therapy: a rationale for the development of monthly oral dosing of ibandronate , 2006, Osteoporosis International.

[11]  M. Seibel.  Biochemical markers of bone turnover: part I: biochemistry and variability. , 2005, The Clinical biochemist. Reviews.

[12]  P. Delmas,et al.  Identification of Osteopenic Women at High Risk of Fracture: The OFELY Study , 2005, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[13]  J. Reginster,et al.  Evidence-based guidelines for the treatment of postmenopausal osteoporosis: a consensus document of the Belgian Bone Club , 2005, Osteoporosis International.

[14]  R. Recker,et al.  Bone Remodeling Increases Substantially in the Years After Menopause and Remains Increased in Older Osteoporosis Patients , 2004, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[15]  D. Bauer,et al.  Change in Bone Turnover and Hip, Non‐Spine, and Vertebral Fracture in Alendronate‐Treated Women: The Fracture Intervention Trial , 2004, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[16]  C. Christiansen,et al.  Daily and intermittent oral ibandronate normalize bone turnover and provide significant reduction in vertebral fracture risk: results from the BONE study , 2004, Osteoporosis International.

[17]  R. Eastell,et al.  The impact of monitoring on adherence and persistence with antiresorptive treatment for postmenopausal osteoporosis: a randomized controlled trial. , 2004, The Journal of clinical endocrinology and metabolism.

[18]  V. Naganathan,et al.  Relationship Between Pretreatment Bone Resorption and Vertebral Fracture Incidence in Postmenopausal Osteoporotic Women Treated With Risedronate , 2003, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[19]  J de Campo,et al.  Evidence-based guidelines. , 2004, Australasian radiology.

[20]  R. Eastell,et al.  Relationship of Early Changes in Bone Resorption to the Reduction in Fracture Risk With Risedronate , 2003, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[21]  M. Seibel.  Biochemical markers of bone metabolism in the assessment of osteoporosis: Useful or not? , 2003, Journal of endocrinological investigation.

[22]  R. Baumgartner,et al.  Critical differences in the serial measurement of three biochemical markers of bone turnover in the sera of pre- and postmenopausal women. , 2001, Clinical biochemistry.

[23]  C. Christiansen,et al.  Bone Resorption in Post-menopausal Women with Normal and Low BMD Assessed with Biochemical Markers Specific for Telopeptide Derived Degradation Products of Collagen Type I , 2001, Calcified Tissue International.

[24]  W. Geilenkeuser,et al.  Interlaboratory variation of biochemical markers of bone turnover. , 2001, Clinical chemistry.

[25]  P. Delmas,et al.  Biochemical Markers of Bone Turnover, Endogenous Hormones and the Risk of Fractures in Postmenopausal Women: The OFELY Study , 2000, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[26]  P. Delmas,et al.  Serum type I collagen breakdown product (serum CTX) predicts hip fracture risk in elderly women: the EPIDOS study. , 2000, Bone.

[27]  J. Souberbielle,et al.  Differences in the Capacity of Several Biochemical Bone Markers to Assess High Bone Turnover in Early Menopause and Response to Alendronate Therapy , 2000, Osteoporosis International.

[28]  R. Eastell,et al.  Preanalytical Variability of Biochemical Markers of Bone Turnover , 2000, Osteoporosis International.

[29]  P. Ross,et al.  Serum Bone Alkaline Phosphatase and Calcaneus Bone Density Predict Fractures: A Prospective Study , 2000, Osteoporosis International.

[30]  P. Delmas,et al.  Markers of Bone Turnover Predict Postmenopausal Forearm Bone Loss Over 4 Years: The OFELY Study , 1999, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[31]  C. Christiansen,et al.  Monitoring of alendronate treatment and prediction of effect on bone mass by biochemical markers in the early postmenopausal intervention cohort study. , 1999, The Journal of clinical endocrinology and metabolism.

[32]  J. Frederiksen,et al.  Thermal instability of the trimeric structure of the N-terminal propeptide of human procollagen type I in relation to assay technology. , 1999, Clinical chemistry.

[33]  R. G. Nielsen,et al.  Analytical and clinical performance characteristics of Tandem-MP Ostase, a new immunoassay for serum bone alkaline phosphatase. , 1998, Clinical chemistry.

[34]  S B Rosalki,et al.  BIOCHEMICAL MARKERS OF BONE TURNOVER , 1998, International journal of clinical practice.

[35]  T. Miki,et al.  [Biochemical markers of bone metabolism]. , 1998, Nihon rinsho. Japanese journal of clinical medicine.

[36]  P. Ross,et al.  Rapid Bone Loss Is Associated with Increased Levels of Biochemical Markers , 1998, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[37]  J. Devogelaer.  How do you know who needs prevention or treatment? , 1997, Bailliere's clinical rheumatology.

[38]  C. Christiansen,et al.  Measurement of Bone Degradation Products in Serum Using Antibodies Reactive with an Isomerized Form of an 8 Amino Acid Sequence of the C‐Telopeptide of Type I Collagen , 1997, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[39]  W. O'Fallon,et al.  Relationship of Bone Turnover to Bone Density and Fractures , 1997, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[40]  P. Garnero,et al.  Undercarboxylated osteocalcin measured with a specific immunoassay predicts hip fracture in elderly women: the EPIDOS Study. , 1997, The Journal of clinical endocrinology and metabolism.

[41]  A. Phillips.  The Fracture Intervention Trial , 1997, The Lancet.

[42]  R. Parker,et al.  Biochemical Markers of Bone Turnover Reflect Femoral Bone Loss in Elderly Women , 1996, Calcified Tissue International.

[43]  C Marcelli,et al.  Markers of bone resorption predict hip fracture in elderly women: The EPIDOS prospective study , 1996, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[44]  O Johnell,et al.  Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures. , 1996, BMJ.

[45]  J. Risteli,et al.  Immunoassay for intact amino-terminal propeptide of human type I procollagen. , 1996, Clinical chemistry.

[46]  P. Delmas,et al.  Serum undercarboxylated osteocalcin is a marker of the risk of hip fracture: a three year follow-up study. , 1996, Bone.

[47]  P. Delmas,et al.  Increased bone turnover in late postmenopausal women is a major determinant of osteoporosis , 1996, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[48]  A. Hofman,et al.  Case-control analysis of bone resorption markers, disability, and hip fracture risk: the Rotterdam study , 1996, BMJ.

[49]  C. Christiansen,et al.  Different effects of bisphosphonate and estrogen therapy on free and peptide‐bound bone cross‐links excretion , 1995, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[50]  R. Eastell,et al.  Apparent instability of osteocalcin in serum as measured with different commercially available immunoassays. , 1995, Clinical chemistry.

[51]  C. de la Piedra,et al.  Six osteocalcin assays compared. , 1994, Clinical chemistry.

[52]  Harry K. Genant,et al.  Consensus development conference: diagnosis, prophylaxis, and treatment of osteoporosis. , 1993, The American journal of medicine.

[53]  D. Eyre,et al.  A specific immunoassay for monitoring human bone resorption: Quantitation of type I collagen cross‐linked N‐telopeptides in urine , 1992, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[54]  C. Christiansen,et al.  Effect of menopause and hormone replacement therapy on the urinary excretion of pyridinium cross-links. , 1991, The Journal of clinical endocrinology and metabolism.

[55]  B. Riis,et al.  Role of peak bone mass and bone loss in postmenopausal osteoporosis: 12 year study. , 1991, BMJ.

[56]  J. Risteli,et al.  Radioimmunoassay of the carboxyterminal propeptide of human type I procollagen. , 1990, Clinical chemistry.

[57]  M. Hoylaerts,et al.  Age and sex distribution of alkaline phosphatase isoenzymes by agarose electrophoresis. , 1990, Clinical chemistry.

[58]  J. Devogelaer,et al.  Endocrinological status of postmenopausal osteoporosis. , 1986, Clinics in rheumatic diseases.

[59]  M. Mizruchi,et al.  Osteocalcin in human serum: a circadian rhythm. , 1985, The Journal of clinical endocrinology and metabolism.

[60]  K. Mann,et al.  Effect of renal function on plasma levels of bone Gla-protein. , 1983, The Journal of clinical endocrinology and metabolism.

[61]  R. Eliakim,et al.  [Postmenopausal osteoporosis]. , 1983, Harefuah.

[62]  J. Glass,et al.  Biochemical markers. , 1981, Science.